EuBiologics Co Ltd
KOSDAQ:206650
EuBiologics Co Ltd
Research & Development
EuBiologics Co Ltd
Research & Development Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Research & Development | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
E
|
EuBiologics Co Ltd
KOSDAQ:206650
|
Research & Development
-₩11.9B
|
CAGR 3-Years
7%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Celltrion Inc
KRX:068270
|
Research & Development
-₩218.9B
|
CAGR 3-Years
-91%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
O
|
OliX Pharmaceuticals Inc
KOSDAQ:226950
|
Research & Development
-₩20.9B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
N/A
|
|
|
V
|
Voronoi Inc
KOSDAQ:310210
|
Research & Development
-₩17.9B
|
CAGR 3-Years
-13%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Research & Development
-₩28.4B
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-35%
|
CAGR 10-Years
-31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Research & Development
-₩95.6B
|
CAGR 3-Years
-35%
|
CAGR 5-Years
-31%
|
CAGR 10-Years
N/A
|
|
EuBiologics Co Ltd
Glance View
EuBiologics Co., Ltd. engages in the research, development, and manufacture of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 323 full-time employees. The company went IPO on 2017-01-24. The firm operates its business through two segments. The Vaccine segment manufactures and sells oral cholera vaccines. The Contract Research and Manufacturing Organization (CRMO) segment contracts, researches and manufactures biopharmaceuticals.
See Also
What is EuBiologics Co Ltd's Research & Development?
Research & Development
-11.9B
KRW
Based on the financial report for Sep 30, 2025, EuBiologics Co Ltd's Research & Development amounts to -11.9B KRW.
What is EuBiologics Co Ltd's Research & Development growth rate?
Research & Development CAGR 5Y
-12%
Over the last year, the Research & Development growth was 1%. The average annual Research & Development growth rates for EuBiologics Co Ltd have been 7% over the past three years , -12% over the past five years .
